Vanguard Personalized Indexing Management LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Vanguard Personalized Indexing Management LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 357,546 shares of the biopharmaceutical company's stock after acquiring an additional 47,785 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Pfizer were worth $9,822,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Olistico Wealth LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the second quarter worth $29,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its holdings in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 600 shares during the period. Finally, Financial Connections Group Inc. acquired a new position in Pfizer during the 2nd quarter worth $34,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

NYSE PFE traded down $0.08 on Wednesday, reaching $29.75. The stock had a trading volume of 25,467,924 shares, compared to its average volume of 37,931,785. The stock has a market cap of $168.58 billion, a P/E ratio of -498.75, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.11. The business's 50-day moving average price is $29.30 and its 200 day moving average price is $28.18. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. During the same quarter in the prior year, the firm earned $0.67 EPS. Pfizer's revenue for the quarter was up 2.1% on a year-over-year basis. As a group, equities analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.65%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer's dividend payout ratio is presently -2,799.53%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a "neutral" rating in a research report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a "neutral" rating to an "outperform" rating and lifted their price target for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Thursday, August 1st. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. Finally, Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.